Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
Saved in:
| Title: | Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies. |
|---|---|
| Authors: | Hamilton MP; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA., Alizadeh AA; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, 94305, USA. |
| Source: | Transplantation and cellular therapy [Transplant Cell Ther] 2024 Oct; Vol. 30 (10), pp. 936-938. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
